ArticleEuropean journal of microbiology & immunology2025
Gall bladder sludge and biliary pseudolithiasis as rare complications of ceftriaxone therapy in adult patients - A case report including sonographic workup.
Article in European journal of microbiology & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ceftriaxone-induced biliary pseudolithiasis is a disease entity frequently observed in children, while it is rarely seen in adult patients. We provide a thorough sonographic workup of the case to guide sonographers confronted with it. Case report: A 41-years-old male patient with sonographically confirmed, culture-negative endocarditis accompanied by repeated fever episodes received 4g ceftriaxone per day next to ampicillin and gentamicin as an element of his antibiotic therapy. At day 4 of treatment, signs of gall bladder sludge and biliary pseudolithiasis were first seen in sonography. At day 17, abdominal pain over 30 min and increased liver and pancreatic enzymes pointed towards temporal duct obstruction as a complication and ceftriaxone therapy had to be preterm cancelled. A sonographic work-up of the stepwise improvement of the sonographic findings after the end of the ceftriaxone therapy is provided, a reemergence of endocarditis was not observed. Discussion: The case reminds of a rarely recognized, usually reversible side effect of high-dose ceftriaxone therapy and its complications. The sonographic work-up may serve as guidance for clinicians during follow-up assessments. Conclusions: Although ceftriaxone allows usually well-tolerated antimicrobial therapies, biliary pseudolithiasis should be kept in mind as a rare but sometimes non-ignorable side effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.